Large-Scale Purification and Characterization of Malaria Vaccine Candidate Antigen Pvs25H for Use in Clinical Trials
- 1 June 2002
- journal article
- Published by Elsevier in Protein Expression and Purification
- Vol. 25 (1), 87-96
- https://doi.org/10.1006/prep.2001.1613
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- The neglected burden of Plasmodium vivax malariaThe American Journal of Tropical Medicine and Hygiene, 2001
- Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability ofPlasmodium vivaxTo Infect MosquitoesInfection and Immunity, 2000
- Structural conformers produced during malaria vaccine production in yeastYeast, 2000
- Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-119) and T helper epitopes of tetanus toxoidVaccine, 1999
- Sequence Polymorphism in Two Novel Plasmodium vivax Ookinete Surface Proteins, Pvs25 and Pvs28, That Are Malaria Transmission-blocking Vaccine CandidatesMolecular Medicine, 1998
- PATHWAYS AND STRATEGIES FOR DEVELOPING A MALARIA BLOOD-STAGE VACCINEAnnual Review of Immunology, 1998
- Transmission-blocking vaccines: Uses and current status of developmentInternational Journal for Parasitology, 1997
- Insecticide Resistance Issues in Vector-Borne Disease ControlThe American Journal of Tropical Medicine and Hygiene, 1994
- PLASMODIUM VIVAX RESISTANCE TO CHLOROQUINE?The Lancet, 1989
- CHLOROQUINE-RESISTANT FALCIPARUM MALARIA IN THAILANDThe Lancet, 1965